Sign up to save your podcasts
Or
Share 322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
STAT reporter Matt Herper joins us to break down all the angles of this week's tumultuous week in cancer immunotherapy, including his up-close look at Summit co-CEO Bob Duggan. We also discuss the latest news in the life sciences, including Moderna pruning its pipeline and its spending, plus results from a study that tested a GLP-1 drug in children.
View all episodes
By STAT
4.5
309309 ratings
STAT reporter Matt Herper joins us to break down all the angles of this week's tumultuous week in cancer immunotherapy, including his up-close look at Summit co-CEO Bob Duggan. We also discuss the latest news in the life sciences, including Moderna pruning its pipeline and its spending, plus results from a study that tested a GLP-1 drug in children.
More shows like The Readout Loud
View all
Planet Money
30,726 Listeners
Odd Lots
1,938 Listeners
What the Health? From KFF Health News
493 Listeners
The Indicator from Planet Money
9,530 Listeners
The Journal.
6,068 Listeners
Tradeoffs
389 Listeners
Biotech 2050 Podcast
62 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Dwarkesh Podcast
516 Listeners
Hard Fork
5,526 Listeners
Biotech Hangout
20 Listeners
Ground Truths
51 Listeners
Money Stuff: The Podcast
392 Listeners
The BioCentury Show
12 Listeners